

## **Burzynski Research Institute Signs Research Agreement with the University of Alabama at Birmingham (UAB), Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility**

- For immediate release - Monday September 28, 2009

HOUSTON—(BUSINESS WIRE)—The Burzynski Research Institute, Inc. (BRI) today announced that it has signed a Research Agreement with the UAB Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility (BBSF) that will provide biostatistical and data management support for BRI's ongoing Phase II and Phase III protocol studies of Antineoplaston (ANP) treatment for gliomas.

The BBSF has the experience and capacity to assist BRI with developing statistical analysis plans; database design; data receipt, management, and long term storage; implementation of quality assurance plans; and the generation of data quality, and study outcome data reports for scientific presentations, publications, and reports. The BBSF is continuing to develop new statistical methodologies, new information technology and approaches to databases, new approaches to quality assurance programs, more efficient procedures for incorporating the results of statistical analyses into reports, presentations and publications, and more efficient and cost effective systems for long term data storage, backup, and retrieval.

"We are very enthusiastic about our association with BBFF. While our Research Agreement has only recently been formalized, BBFF has already assisted BRI in the development of a FDA-approved Phase III protocol study of Antineoplaston therapy for glioma and in the development of a novel Phase II protocol study of Antineoplaston therapy for glioma, which is currently being submitted for FDA approval. Both studies involve multiple international sites and BBFF's expertise in international data management will prove invaluable."

**Burzynski Research Institute, Inc.** (OTCBB: [BZYR – News](#)) is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles.

*Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Burzynski Research Institute, Inc. cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to BRI's ability to obtain regulatory approval for Antineoplastons A10 and AS2-1, risks associated with BRI's ability to raise sufficient capital from the development of its technology towards commercialization, and other risks described in BRI's periodic reports filed with the Securities and Exchange Commission. BRI does not undertake to update any such forward- looking statements or to publicly announce developments or events relating to the matters described herein.*

SOURCE: Burzynski Research Institute, Inc.

For Burzynski Research Institute, Inc. Darlene Hodge, 713-335-5636 [Darlene@burzynskiclinic.com](mailto:Darlene@burzynskiclinic.com) or Carolyn Powers, 713.335.5664 [Carolyn@burzynskiclinic.com](mailto:Carolyn@burzynskiclinic.com).